ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions
View by Date

Tuesday, November 15, 2016

9:00AM-11:00AM
Abstract Number: 2604
Ultrasound and Immunological Changes and Associations after One Year of IL-6/IL- 6R Blockade with Tocilizumab in Rheumatoid Arthritis Patients
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster III
9:00AM-11:00AM
Abstract Number: 2330
Ultrasound Imaging in Inclusion Body Myositis
Muscle Biology, Myositis and Myopathies - Poster II: Clinical
9:00AM-11:00AM
Abstract Number: 2685
Ultrasound of the Major Salivary Glands Is a Reliable Imaging Technique for Diagnosing Patients Clinically Suspected with SjöGren’s Syndrome
Sjögren's Syndrome - Poster II: Clinical Science
9:00AM-11:00AM
Abstract Number: 2334
Ultrasound-Guided Facet Joint Injections through a Longitudinal Approach
Orthopedics, Low Back Pain and Rehabilitation - Poster
9:00AM-11:00AM
Abstract Number: 2871
Unaffected Lupus Relatives Are Distinguished from SLE Patients and Unaffected Individuals Not Related to SLE Patients By Lupus-Specific Connective Tissue Disease Questionnaire Scores, Autoantibodies, and Distinct Soluble Mediators
Systemic Lupus Erythematosus – Human Etiology and Pathogenesis - Poster II
9:00AM-11:00AM
Abstract Number: 2342
Understanding Patient Barriers and Facilitators to Healthy Eating and Physical Activity before and after Knee Replacement
Orthopedics, Low Back Pain and Rehabilitation - ARHP Poster
9:00AM-11:00AM
Abstract Number: 2764
Unhappiness Is Related to Worse Outcomes for Patients with Ankylosing Spondylitis and Increased Impairment in Daily Life Activities, Results from a Multinational Real-World Sample
Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster III
9:00AM-11:00AM
Abstract Number: 2130
Unloading Results in Rapid Loss of TGFβ Signaling in Cartilage: Role of Loading-Induced TGF-Β Signaling in Maintenance of Articular Chondrocyte Phenotype?
Biology and Pathology of Bone and Joint - Poster I
9:00AM-11:00AM
Abstract Number: 2576
uPAR Promotes Tumor-like Biologic Role of Fibroblast-like Synoviocytes through PI3K/Akt Signaling Pathway in Patients with Rheumatoid Arthritis
Rheumatoid Arthritis – Human Etiology and Pathogenesis - Poster III
9:00AM-11:00AM
Abstract Number: 2391
Update on the Juvenile Systemic Sclerosis Inception Cohort Project.  Characteristics of the First 80 Patients at First Assessment
Pediatric Rheumatology – Clinical and Therapeutic Aspects - Poster III: Systemic JIA, Autoinflammatory Syndromes, Scleroderma, Vasculitis, Miscellaneous
9:00AM-11:00AM
Abstract Number: 2294
Uric Acid Production and Blood Pressure: The Role of Uric Acid Concentration As Well As Uric Acid Production
Metabolic and Crystal Arthropathies - Poster II: Epidemiology and Mechanisms of Disease
9:00AM-11:00AM
Abstract Number: 2823
Urinary Angiostatin, CXCL4 and VCAM-1 As Biomarkers for Lupus Nephritis
Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster III: Biomarkers and Nephritis
9:00AM-11:00AM
Abstract Number: 2825
Urinary BAFF and APRIL Levels: Potential Biomarkers of Active Lupus Nephritis
Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster III: Biomarkers and Nephritis
9:00AM-11:00AM
Abstract Number: 2858
Urinary PF4 and E-Selectin As Novel Biomarkers for Disease Activity and Renal Damage in Lupus Nephritis
Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster III: Biomarkers and Nephritis
9:00AM-11:00AM
Abstract Number: 14L
Use of Intravenous Epoprostenol As a Treatment for the Digital Vasculopathy Associated with the Scleroderma Spectrum of Diseases
ACR Late-Breaking Poster Session
  • «Previous Page
  • 1
  • …
  • 56
  • 57
  • 58
  • 59
  • 60
  • …
  • 69
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology